Molecular targeted therapy: A new avenue in glioblastoma treatment (Review)
| Autor: | El Atat, Oula, Naser, Rayan, Abdelkhalek, Maya, Habib, Ralph Abi, El Sibai, Mirvat |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Oncol Lett |
| ISSN: | 1792-1082 1792-1074 |
| DOI: | 10.3892/ol.2022.13632 |
| Popis: | Glioblastoma, also referred to as glioblastoma multiforme (GBM), is grade IV astrocytoma characterized by being fast-growing and the most aggressive brain tumor. In adults, it is the most prevalent type of malignant brain tumor. Despite the advancements in both diagnosis tools and therapeutic treatments, GBM is still associated with poor survival rate without any statistically significant improvement in the past three decades. Patient's genome signature is one of the key factors causing the development of this tumor, in addition to previous radiation exposure and other environmental factors. Researchers have identified genomic and subsequent molecular alterations affecting core pathways that trigger the malignant phenotype of this tumor. Targeting intrinsically altered molecules and pathways is seen as a novel avenue in GBM treatment. The present review shed light on signaling pathways and intrinsically altered molecules implicated in GBM development. It discussed the main challenges impeding successful GBM treatment, such as the blood brain barrier and tumor microenvironment (TME), the plasticity and heterogeneity of both GBM and TME and the glioblastoma stem cells. The present review also presented current advancements in GBM molecular targeted therapy in clinical trials. Profound and comprehensive understanding of molecular participants opens doors for innovative, more targeted and personalized GBM therapeutic modalities. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|